Previous Study: TRIO033
Next Study: TRIO028
Studies & Results
TRIO032
Treat ER+ight: Treatment of Canadian Postmenopausal Women with ER+ Advanced Breast Cancer in the Real-World Setting with Hormone Therapy ± Targeted Therapy (CRAD001YCA09)
View FDA Study
Presentations
ESMO Congress 2017
Catherine Doyle
Real-world everolimus experience in postmenopausal HR+ HER2- advanced breast cancer women: Treat ER+ight Canadian prospective observational study 2nd subgroup analysis
SABCS 2019
Doyle C, et al.
Exploratory Analysis of Treat ER+ight: A Canadian Prospective Real-World Observational Study in HR+ Advanced Breast Cancer
Publications
For information on any of TRIO's clinical trials, please contact Valérie Bee, Director Project Management at valerie.bee@trioncology.org
Presentations
ESMO Congress 2017
Catherine Doyle
Real-world everolimus experience in postmenopausal HR+ HER2- advanced breast cancer women: Treat ER+ight Canadian prospective observational study 2nd subgroup analysis
SABCS 2019
Doyle C, et al.
Exploratory Analysis of Treat ER+ight: A Canadian Prospective Real-World Observational Study in HR+ Advanced Breast Cancer
Publications
For information on any of TRIO's clinical trials, please contact Valérie Bee, Director Project Management at valerie.bee@trioncology.org